PT-141 (also known as Bremelanotide) from Super Human Peptides UK is a synthetic, cyclic heptapeptide. It is a direct metabolite and derivative of Melanotan II (MT-2). In laboratory research, PT-141 is the premier model for investigating the neurobiology of sexual arousal and libido.
While MT-2 binds strongly to the MC1 receptor to induce tanning, PT-141 was specifically engineered to isolate the melanocortin 4 receptor (MC4R) pathways in the central nervous system. Researchers utilize this peptide to study psychogenic arousal—meaning it works by stimulating the brain's sexual desire pathways rather than directly altering vascular blood flow. Produced under GMP-compliant conditions and verified for 99% purity or higher, PT-141 is a critical tool for preclinical models of both male erectile dysfunction and female hypoactive sexual desire disorder.
- —Central Nervous System Agonist: Targets the MC4 receptor in the hypothalamus.
- —Non-Vascular Mechanism: Studies arousal independently of the cardiovascular system.
- —Isolated Arousal Pathways: Specifically engineered to remove the heavy melanogenesis (tanning) effects of MT-2.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —MC4R Activation: Studying the direct stimulation of neurons in the medial preoptic area (mPOA) of the hypothalamus.
- —Dopamine Release: Investigating the downstream release of dopamine triggered by melanocortin receptor activation.
- —Female Sexual Arousal: Preclinical models exploring the restoration of libido in models of hypoactive sexual desire disorder (HSDD).
- —PDE5-Independent Pathways: Researching alternatives for subjects that do not respond to traditional phosphodiesterase type 5 inhibitors (e.g., sildenafil).
- —Autonomic Nervous System: Measuring temporary, dose-dependent increases in blood pressure or heart rate following central activation.
PT-141 was discovered during the clinical development of Melanotan II. When researchers noted that MT-2 caused profound spontaneous arousal in laboratory models, they synthesized PT-141 to isolate this specific effect while minimizing the tanning properties. Extensive laboratory and clinical literature has demonstrated that PT-141 acts directly on the brain to initiate the arousal cascade.
In animal models, administration of PT-141 reliably induces erectile activity in males and lordosis (mating behavior) in females. Because it circumvents the vascular system entirely, it has become a major focus for researching sexual dysfunction linked to psychological factors, nerve damage, or non-responsiveness to traditional vascular therapies.
- 1.Diamond, L.E. et al., "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141," International Journal of Impotence Research, 2004.
- 2.Safarinejad, M.R. et al., "Evaluation of the safety and efficacy of PT-141, a melanocortin receptor agonist, for the treatment of erectile dysfunction," International Journal of Impotence Research, 2008.
- 3.Rosen, R.C. et al., "Bremelanotide for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled, dose-finding study," Journal of Women's Health, 2004.
- 4.Molinoff, P.B. et al., "PT-141: A melanocortin agonist for the treatment of sexual dysfunction," Annals of the New York Academy of Sciences, 2003.
